From: Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up
 | Stage 1 (n = 181) | Advanced (n = 77) | |
---|---|---|---|
Median age, years (range) | 36 (14–64) | 38 (14–61) | |
Initial clinical staging, n (%) | Localised | 184 (100) | 15 (19) |
Advanced | - | 62 (81) | |
Surgical management, n (%) | Orchidectomy | 184 (100) | 71 (92) |
Retroperitoneal lymph node dissection | - | 2 (3) | |
Other surgery (metastectomy) | - | 2 (3) | |
Adjuvant therapy for stage 1 seminoma, n (%) | Chemotherapy | 33 (18) | 3 (20)* |
Radiation therapy | 82 (45) | 3 (20)* | |
None | 63 (34) | 9 (60)* | |
Unknown | 6 (3) | 0 (0)* | |
Treatment(s) for advanced/recurrent testicular seminoma, n (%) | Chemotherapy | - | 43 (56) |
Radiation therapy | - | 40 (52) | |
Surgery | - | 4 (5) | |
Number of FDG-PET/CT per patient, n (range) | 1 (1–3) | 2 (1–7) | |
Median follow-up from initial diagnosis with seminoma, years (range) | 6.4 (0–17) | 9.3 (0–25) |